# Autologous Immune Cell Therapy in Combination With LHRH-a in Patients With mCRPC

> **NCT03085966** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Shanghai AbelZeta Ltd.** · enrollment: 30 (estimated)

## Conditions studied

- Metastatic Castration-resistant Prostate Cancer

## Interventions

- **BIOLOGICAL:** autologous immune cell therapy

## Key facts

- **NCT ID:** NCT03085966
- **Lead sponsor:** Shanghai AbelZeta Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2017-02-27
- **Primary completion:** 2019-10-27
- **Final completion:** 2019-12-27
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2017-03-21

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03085966

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03085966, "Autologous Immune Cell Therapy in Combination With LHRH-a in Patients With mCRPC". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT03085966. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*